Raymond James cuts UnitedHealth valuation target while keeping Outperform rating
On October 15, Raymond James reduced its UnitedHealth Group price objective to $450 from $475 and retained an Outperform rating. The change followed UnitedHealth’s third-quarter 2026 adjusted EPS of $4.69 and its increased 2026 EPS outlook of at least $20.50, with valuation concerns tied to possible regulatory changes and midterm-election risks.
Why it matters
The lower objective establishes a reduced valuation reference for UnitedHealth shares, while the unchanged Outperform view signals that Raymond James still expects favorable risk-adjusted performance. UnitedHealth’s higher earnings outlook provides an offsetting company-specific support for investors evaluating the revised target.
Key facts
- 1Raymond James set a $450 price objective for UnitedHealth, compared with its previous $475 objective, while keeping an Outperform rating. investing.com
- 2UnitedHealth reported adjusted third-quarter 2026 earnings per share of $4.69 and lifted its 2026 earnings outlook to at least $20.50 from $19.50 to $20.00. investing.com
- 3Raymond James attributed the valuation change to investor concerns about midterm elections and potential changes involving risk adjustment and Stars. investing.com
Open questions
- Material 1 gives two different estimates for UnitedHealth’s adjusted third-quarter 2026 EPS comparison: $4.12 in one passage and $4.14 in another.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.